Syncona Ltd with ticker (LON:SYNC) now has a potential upside of 28.6% according to Peel Hunt LLP.
Peel Hunt LLP set a target price of 279 GBX for the company, which when compared to the Syncona Ltd share price of 199 GBX at opening today (08/11/2021) indicates a potential upside of 28.6%. Trading has ranged between 162 (52 week low) and 280 (52 week high) with an average of 809,552 shares exchanging hands daily. The market capitalisation at the time of writing is £1,326,077,144.
Syncona Ltd is a closed-ended investment healthcare company which focuses on investing in and building global leaders in life science. The Company operates in two segments: life science portfolio and fund investments. The Company’s portfolio is made up of a small group of healthcare companies. The Company intends to achieve the investment objective through investments in long-only funds, hedge funds, private equity funds, infrastructure funds, credit and fixed income and real estate funds. The Company makes its life science investments through Syncona Holdings Limited. The Company makes its fund investments through Syncona Investments LP Incorporated.
Syncona Ltd 28.6% potential upside indicated by Peel Hunt LLP
[shareaholic app="share_buttons" id_name="post_below_content"]
- Written by: Anthony Fox
Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
Syncona Ltd (LON:SYNC) commits $42.5 million to Beacon Therapeutics' $170 million Series B financing to advance treatments for blinding retinal diseases.
Syncona Ltd (LON:SYNC) expands its life science portfolio with €30M in iOnctura and £16.5M in Yellowstone Biosciences, enhancing their oncology innovations.
Syncona Limited has issued its quarterly update, reporting an increase in net assets and a positive NAV per share return. The company's life science portfolio also saw significant growth. Read more for details. #Syncona #quarterlyupdate #lifescienceinvestment
Syncona Ltd notes further safety and enzyme activity data from its portfolio company, Freeline Therapeutics, on its gene therapy candidate for Gaucher disease.
